Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra11Published on the World Wide Web on 1 December 2000.

Costa, Gustavo; Abin-Carriquiry, J.A.; Dajas, Federico

doi:10.1016/s0006-8993(00)03087-0

Cited by 134Parkinson's Disease Mechanisms and TreatmentsNicotinic Acetylcholine Receptors StudyNeurotransmitter Receptor Influence on Behavior

Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra11Published on the World Wide Web on 1 December 2000.

Costa, Gustavo, Abin-Carriquiry, J.A., Dajas, Federico·2001·Brain Research

DOI 10.1016/s0006-8993(00)03087-0

Open this paper in CoChat — free account

Abstract

While the work of several groups has shown the neuroprotective effects of nicotine in vitro, evidences for the same effects in vivo are controversial, mainly regarding neuroprotection in experimental models of Parkinson's disease. In this context, we investigated the capability of various systemic administration schedules of nicotine to prevent the loss of striatal dopamine levels produced by partial or extensive 6-hydroxydopamine (6-OHDA) lesion of rat substantia nigra (SN). Eight days after 6- and 10-microg injections of 6-OHDA in the SN there was a significant decrease of dopamine concentrations in the corpus striatum (CS) and a concomitant increase in dopamine turnover. While 10 microg 6-OHDA produced an almost complete depletion of dopamine in the SN, 6 microg decreased dopamine levels by 50%. Subcutaneous nicotine (1 mg/kg) administered 4 h before and 20, 44 and 68 h after 6 microg 6-OHDA, prevented significantly the striatal dopamine loss. Administered only 18 or 4 h before or only 20, 44 and 68 h after, nicotine failed to counteract the loss of dopamine or the increase in dopamine turnover observed in the CS. Nicotine also failed to prevent significantly the decrease of striatal dopamine levels produced by the 10-microg 6-OHDA intranigral dose. Chlorisondamine, a long-lasting nicotinic acetylcholine receptor antagonist, reverted significantly the nicotinic protective effects on dopamine concentrations. These results are showing that putative neuroprotective effects of nicotine in vivo depend on an acute intermittent administration schedule and on the extent of the brain lesion.

Integrity signals

Registry

Crossref · 10.1016/s0006-8993(00)03087-0

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nicotine protects rodent DA neurons against toxin-induced cell loss.
“Nicotine protects rodent DA neurons agonist toxin-induced cell loss (21–24), but these neuroprotective effects are absent in α4 nAChR knockout (KO) mice (22).”
From Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery (2009) · cites this paper as [24]

The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585 · see citing works
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985 · see citing works
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. A., & SEITELBERGER, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,650 · see citing works
Autoxidation versus Covalent Binding of Quinones as the Mechanism of Toxicity of Dopamine, 6-Hydroxydopamine, and Related Compounds toward C1300 Neuroblastoma Cells in Vitro
Graham, D. G., Tiffany, S. M., BELL, W. R., & Gutknecht, W. F. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13536-0 · Cited by 953 · see citing works
Psychopharmacology: The Fourth Generation of Progress
Kramlinger, K. G. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.10.1021-a · Cited by 779 · see citing works
Principles of Neuropsychopharmacology
Feldman, R. S., Meyer, J. S., & Quenzer, L. F. (1997) · Cited by 437 · see citing works
Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets
Lloyd, G. K., & Williams, M. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35314-5 · Cited by 311 · see citing works
6-Hydroxydopamine Lesion of the Rat Substantia Nigra: Time Course and Morphology of Cell Death
Jeon, B. S., Jackson-Lewis, V. R., & Burke, R. E. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0016 · Cited by 291 · see citing works
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 290 · see citing works
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle
Rosenblad, C., Kirik, D., Devaux, B., Moffat, B., PHILLIPS, H. S., & Björklund, A. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00566.x · Cited by 261 · see citing works
Nicotine-induced protection of cultured cortical neurons againstN-methyl-D-aspartate receptor-mediated glutamate cytotoxicity
Akaike, A., Tamura, Y., Yokota, T., Shimohama, S., & Kimura, J. (1994) · Brain Research · doi:10.1016/0006-8993(94)91678-0 · Cited by 240 · see citing works
Dopamine, 6-hydroxydopamine, iron, and dioxygen — their mutual interactions and possible implication in the development of Parkinson's disease
Linert, W., Herlinger, E., Jameson, R. F., Kienzl, E., Jellinger, K. A., & Youdim, M. B. H. (1996) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(96)00020-8 · Cited by 238 · see citing works
Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors
Maggio, R., Riva, M. A., Vaglini, F., Fornai, F., Molteni, R., Armogida, M., Racagni, G., & Corsini, G. U. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062439.x · Cited by 218 · see citing works
Free Radical‐Generated Neurotoxicity of 6‐Hydroxydopamine
Kumar, R., Agarwal, A. K., & Seth, P. K. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041703.x · Cited by 203 · see citing works
Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β-amyloid toxicity
Kihara, T., Shimohama, S., Urushitani, M., Sawada, H., Kimura, J., Kume, T., Maeda, T., & AKAIKE, A. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00138-3 · Cited by 193 · see citing works
The α7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca2+ dependent mechanism
Dajas‐Bailador, F., Lima, P. A., & Wonnacott, S. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00127-1 · Cited by 182 · see citing works
Time Course of Adaptations in Dopamine Biosynthesis, Metabolism, and Release Following Nigrostriatal Lesions: Implications for Behavioral Recovery from Brain Injury
Altar, C. A., Marien, M. R., & Marshall, J. F. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb04106.x · Cited by 161 · see citing works
Sequential Administration of GDNF into the Substantia Nigra and Striatum Promotes Dopamine Neuron Survival and Axonal Sprouting but Not Striatal Reinnervation or Functional Recovery in the Partial 6-OHDA Lesion Model
Rosenblad, C., Kirik, D., & Björklund, A. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7296 · Cited by 161 · see citing works
Differential Regulation of Neuronal Nicotinic Receptor Binding Sites Following Chronic Nicotine Administration
Flores, C. M., Dávila‐García, M. I., Ulrich‐Lai, Y. M., & Kellar, K. J. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69052216.x · Cited by 142 · see citing works
Efficacy of Brain‐Derived Neurotrophic Factor and Neurotrophin‐3 on Neurochemical and Behavioral Deficits Associated with Partial Nigrostriatal Dopamine Lesions
Altar, C. A., Boylan, C. B., Fritsche, M., Jones, B. E., Jackson, C., Wiegand, S. J., Lindsay, R. M., & Hyman, C. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63031021.x · Cited by 138 · see citing works
Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage
Shimohama, S., Greenwald, D. L., Shafron, D. H., et al. (1998) · Brain Research · doi:10.1016/s0006-8993(97)00194-7 · Cited by 135 · see citing works
Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use
Court, J. A., Lloyd, S., Thomas, N., Piggott, M. A., Marshall, E. F., Morris, C. M., Lamb, H., Perry, R. H., Johnson, M., & Perry, E. K. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00088-8 · Cited by 135 · see citing works
A RETROSPECTIVE STUDY OF SMOKING IN PARKINSON'S DISEASE1
Nefzger, M. D., QUADFASEL, F. A., & KARL, V. C. (1968) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120874 · Cited by 130 · see citing works
Dose‐Response Relationship for Nicotine‐Induced Up‐Regulation of Rat Brain Nicotinic Receptors
Rowell, P. P., & Li, M. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68051982.x · Cited by 124 · see citing works
Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection
Janson, A. M., Fuxé, K., Agnati, L. F., Kitayama, I. T., Härfstrand, A., Andersson, K., & Goldstein, M. (1988) · Brain Research · doi:10.1016/0006-8993(88)90092-3 · Cited by 114 · see citing works
Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity
Marin, P., Maus, M., Desagher, S., Glowinski, J., & Prémont, J. (1994) · Neuroreport · doi:10.1097/00001756-199410000-00035 · Cited by 110 · see citing works
Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system
Robinson, T. E., Mocsary, Z., Camp, D., & Whishaw, I. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-05-02687.1994 · Cited by 109 · see citing works
In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418
Donnelly‐Roberts, D. L., Xue, I. C., Arnerić, S. P., & Sullivan, J. P. (1996) · Brain Research · doi:10.1016/0006-8993(96)00063-7 · Cited by 103 · see citing works
Characterization of the neuroprotective and toxic effects of α7 nicotinic receptor activation in PC12 cells
Li, Y., Papke, R. L., He, Y., Millard, W. J., & Meyer, E. M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01372-4 · Cited by 103 · see citing works
Basic Fibroblast Growth Factor Stimulation of Glial Cells Protects Dopamine Neurons from 6‐Hydroxydopamine Toxicity: Involvement of the Glutathione System
Hou, J. G., Cohen, G., & Mytilineou, C. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010076.x · Cited by 95 · see citing works
Differential effects of acute and chronic nicotine treatment on MPTP-(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse
Janson, A. M., Fuxé, K., & Goldstein, M. (1992) · Journal of Molecular Medicine · doi:10.1007/bf00184656 · Cited by 84 · see citing works
Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat
Belluardo, N., Blum, M., Mudò, G., Andbjer, B., & Fuxé, K. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00323-0 · Cited by 83 · see citing works
Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo
Ferger, B., Spratt, C., Earl, C. D., Teismann, P., Oertel, W. H., & Kuschinsky, K. (1998) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00005264 · Cited by 78 · see citing works
Nicotine Enhances 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Neurotoxicity
Behmand, R. A., & Harik, S. I. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09786.x · Cited by 50 · see citing works
Blockade of nicotinic receptor‐mediated release of dopamine from striatal synaptosomes by chlorisondamine administeredin vivo
El-Bizri, H., & Clarke, P. B. S. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb14750.x · Cited by 48 · see citing works
Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons
Garrido, R., Małecki, A., Hennig, B., et al. (2000) · Brain Research · doi:10.1016/s0006-8993(00)01977-6 · Cited by 36 · see citing works
The nicotinic acetylcholine receptor agonist (±)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain
Belluardo, N., Mudò, G., Blum, M., Cheng, Q., Caniglia, G., Dell’Albani, P., & Fuxé, K. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00266-1 · Cited by 34 · see citing works
Chapter 25 Protective effects of chronic nicotine treatment on lesioned nigrostriatal dopamine neurons in the male rat
Janson, A. M., Fuxé, K., Agnati, L. F., Jansson, A., Bjelke, B., Sundström, E., Andersson, K., Härfstrand, A., Goldstein, M., & Owmand, C. (1989) · Progress in brain research · doi:10.1016/s0079-6123(08)62485-1 · Cited by 33 · see citing works
Chronic continuous infusion of (−)nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6-hydroxydopamine-lesioned rat
Blum, M., Wu, G., Mudò, G., Belluardo, N., Andersson, K., Agnati, L. F., & Fuxé, K. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00364-o · Cited by 30 · see citing works
Neurite outgrowth, RGD-dependent, and RGD-independent adhesion of identified molluscan motoneurons on selected substrates
Wildering, W. C., Hermann, P. M., & Bulloch, A. G. (1998) · Journal of Neurobiology · doi:10.1002/(sici)1097-4695(199804)35:1 · Cited by 23 · see citing works
Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation
Dajas‐Bailador, F., Martinez-Borges, A. R., Costa, G., et al. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00989-5 · Cited by 19 · see citing works
Self-citation
Persistent nicotinic blockade by chlorisondamine of noradrenergic neurons in rat brain and cultured PC12 cells
Reuben, M., Louis, M. S., & Clarke, P. B. S. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702215 · Cited by 19 · see citing works
Chronic administration of nicotine fails to alter the MPTP-induced neurotoxicity in mice
Fung, Y. K., Fiske, L. A., & Lau, Y. (1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90075-h · Cited by 16 · see citing works
Intraneuronal accumulation and persistence of radiolabel in rat brain followingin vivoadministration of [3H]‐chlorisondamine
El-Bizri, H., Rigdon, M. G., & Clarke, P. B. S. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15102.x · Cited by 15 · see citing works
GDNF partially protects grafted fetal dopaminergic neurons against 6-hydroxydopamine neurotoxicity
Yurek, D. M., & Fletcher, A. M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01921-6 · Cited by 12 · see citing works

Flagged first, then by citations

Sorted by citations

Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery
Lester, H. A., Xiao, C., Srinivasan, R., Son, C. D., Miwa, J., Pantoja, R., Banghart, M. R., Dougherty, D. A., Goate, A. M., & Wang, J. C. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9090-7 · Cited by 163 · see citing works
Nicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154 · see citing works
The neuronal nicotinic acetylcholine receptors α4* and α6* differentially modulate dopamine release in mouse striatal slices
Meyer, E. L., Yoshikami, D., & McIntosh, J. M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05266.x · Cited by 58 · see citing works
Nicotine partially protects against paraquat‐induced nigrostriatal damage in mice; link to α6β2* nAChRs
Khwaja, M., McCormack, A., McIntosh, J. M., Di Monte, D. A., & Quik, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04177.x · Cited by 54 · see citing works
Antioxidant effect of Spirulina (Arthrospira) maxima in a neurotoxic model caused by 6-OHDA in the rat striatum
Tobón-Velasco, J. C., Palafox-Sánchez, V., Mendieta, L., García, E., Santamaría, A., Chamorro-Cevallos, G., & Limón, I. D. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0976-2 · Cited by 47 · see citing works

Authors: Costa, G., Abin-Carriquiry, J. A., & Dajas, F.
Affiliations: Instituto de Investigaciones Biológicas Clemente Estable (UY)
Venue: Brain Research
Publisher: Elsevier BV
Published: 2001-01
Volume: 888
Issue: 2
Pages: 336-342
ISSN: 0006-8993 (ISSN-L)
DOI: 10.1016/s0006-8993(00)03087-0
OpenAlex: W2023903683
Cited by: 134
References: 45
Citations by year: 2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 2 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 8
FWCI: 6.10
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Brain Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: nicotine, neuroprotection, Parkinson's disease, 6-hydroxydopamine lesion, substantia nigra, striatal dopamine, dopamine turnover, nicotinic acetylcholine receptors, chlorisondamine, administration schedule, dopamine depletion
MeSH terms: Animals, Chlorisondamine, Corpus Striatum, Disease Models, Animal, Dopamine, Dose-Response Relationship, Drug, Drug Administration Schedule, Injections, Subcutaneous, Male, Nicotine, Parkinson Disease, Secondary, Substantia Nigra, 3,4-Dihydroxyphenylacetic Acid, Oxidopamine, Rats, Sprague-Dawley, Neuroprotective Agents, Nicotinic Agonists, Nicotinic Antagonists, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra11Published on the World Wide Web on 1 December 2000.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks